Hyperion Wins NDA Approval for UCD Drug Developed With Support from…

PharmaDirections congratulates Hyperion Therapeutics on achieving an NDA approval for their RAVICTI™ (glycerol phenylbutyrate) Liquid for Treatment of Urea Cycle Disorders . PharmaDirections is proud...

(PRWeb February 27, 2013)

Read the full story at http://www.prweb.com/releases/2013/2/prweb10442980.htm


Comments are closed.